Randomize Trial of Cisplatin plus Gemcitabine with either Sorafenib or Placebo as First-line Therapy for Non-small Cell Lung Cancer

Randomize Trial of Cisplatin plus Gemcitabine with either Sorafenib or Placebo as First-line Therapy for Non-small Cell Lung Cancer

Background and objective Platinum-based chemotherapy doublets reached an efficacy plateau in nonsmall-cell lung cancer (NSCLC). This randomized controlled study prospectively assessed the efficacy and safety of cisplatin plus gemcitabine with either Sorafenib or placebo as first-line therapy for NSC...

Full description

Bibliographic Details
Main Authors: Yan WANG, Lin WANG, Yutao LIU, Shufei YU, Xiangru ZHANG, Yuankai SHI, Yan SUN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2011-03-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
Chemotherapy
Sorafenib
Response
Online Access:http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2011.03.10&path[]=3671

Internet

http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2011.03.10&path[]=3671

Similar Items